Top market ‘AI in biotech’ stories
Combatting AI hesitation, muscle aging genes unlocked, Roche x Dyno gene therapy deal, and more.
We’re introducing a new monthly series from Ardigen—your curated selection of the latest news in AI for biotech and pharma. In just 3–4 minutes, catch up on the innovations reshaping drug discovery and biomedical research. We’ll publish fresh insights on the second Tuesday of each month, so you can stay informed and inspired. Happy reading!
In today’s edition:
- 🤖AI tools encounter hesitation in the biomedical industry
- 💪AI unlocks the secret genes behind muscle aging
- 📄Scientific papers that mention AI get more citations
- 🤝Roche expands Dyno gene therapy collaboration
AI hesitation: Biomedical researchers tread carefully with AI tools
A recent survey from nonprofit research firm Ithaka S+R shows that while over 60% of biomedical scientists have experimented with AI tools like ChatGPT, only 24% use these tools on a regular basis. Most of the responders are cautious due to concerns about accuracy and ethics.
source: sr.ithaka
AI unlocks key genes behind muscle aging
Researchers at Nottingham Trent University used AI to pinpoint critical genes that may drive muscle aging. The study, published in Journal of Cachexia, Sarcopenia and Muscle, highlights the role of AI in identifying new avenues for drug development to slow down age-related muscle loss.
source: Sci tech Daily
Scientific papers that mention AI get a citation boost
AI isn’t just a trendy topic—it’s helping scientists gain more attention for their work. A Nature survey of 1,600 researchers worldwide found that papers mentioning AI are more likely to rank among the top 5% most-cited in their fields. These papers also receive more cross-disciplinary citations, hinting at AI’s broad appeal and relevance across sciences.
source: Nature
Roche expands Dyno gene therapy partnership with a $1B bet on AI-driven delivery
The Swiss pharmaceutical giant Roche has signed a new deal with Dyno, worth over $1 billion, to further develop AI-enhanced gene therapy delivery tools. Roche is paying $50 million upfront, with the aim of designing better adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases, a high-priority area for the company.
source: Fierce Biotech
